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It started 30 years ago with vitamin A: the idea that some
cancers might be caused by vitamin deﬁciencies. Animal
experimental models led us to the notion that cancer risk
might be ‘‘materially’’ reduced by supplementation with
beta-carotene, a retinol precursor (1). Although that idea
was seductive, we were all disappointed when 2 large ran-
domized controlled trials that began in 1985 in Finland and
the United States reported an 18% increased risk of lung
cancer caused by high-dose beta-carotene supplementation
and a 28% increased lung cancer risk caused by a combina-
tion of beta-carotene and retinol (2, 3). The vitamin A era
was over.
Next came the B vitamins. Again, based on animal ex-
perimental evidence and supported by epidemiologic evi-
dence of connections between diets low in B vitamins and
increased cancer risk, a large randomized controlled trial
was begun in 1985 in central China, where micronutrient
deﬁciency was common and where rates of cancers of the
stomach and esophagus were extraordinarily high. Nonethe-
less, several years of supplementation with a combination of
riboﬂavin (vitamin B2) and niacin (vitamin B3) had no effect
on incidence of upper gastrointestinal cancers (4). Interest in
folic acid (vitamin B9) persisted, though, in part because of
its striking effect on neural tube birth defects, coupled with
speculation about possible beneﬁts of food fortiﬁcation for
diseases such as colorectal cancer that were inversely asso-
ciated with diets rich in folate-containing foods and supple-
ments. However, a 7-year randomized controlled trial found
that high-dose folic acid supplements actually increased risk
of colorectal adenomas (5). The vitamin B era was over.
Next came vitamin C, a popular charge led by none other
than Linus Pauling, the brilliant and charismatic 2-time
Nobel laureate. Of all the cancers thought to be related to
vitamin C deﬁciency, gastric cancer led the way, and of all
the places on Earth where a vitamin C deﬁciency correction
trial might yield beneﬁts for gastric cancer, Linxian, China,
would be the best. Indeed, vitamin C was tested in the
Linxian trial, but just as for the B vitamins, vitamin C pro-
duced no change in gastric cancer rates (6).
Next, slightly out of alphabetical order, came vitamin E.
In 1993, we launched headlong into a love affair with vita-
min E fueled by compelling observations that those who
chose to take vitamin E supplements were at lower risk of
heart disease (7, 8). Vitamin E supplementation became the
rage as several large, randomized controlled trials were
mounted. When those results ﬁnally came in, the ﬁndings
were again disappointing: vitamin E supplementation of-
fered no beneﬁt for heart disease, and it slightly increased
overall mortality (9, 10). In the meantime, though, because
of a secondary observation that prostate cancer incidence
was lower in the vitamin E arm of the same Finnish trial that
tested beta-carotene (vitamin E had also been included
as a factor) (11), a large factorial trial of vitamin E (and
selenium) was carried out for reducing prostate cancer
incidence. Disappointment again: there was no effect of
either selenium or vitamin E on incidence of prostate cancer
(12). The vitamin E era ended in a whimper.
Over 2 decades of searching for an anticancer vitamin, we
had seemed to skip over vitamin D in its proper alphabetical
sequence. In my role as a member of the World Cancer
Research Fund Expert Panel that considered the evidence
from commissioned meta-analyses of the world’s literature
on nutritional epidemiology, I remember feeling concern as
we ﬁnished our work that we might have underestimated the
importance of vitamin D because the bulk of the evidence
available at that time was derived from ecologic studies
(13). Subsequently, the International Agency for Research
on Cancer conducted a comprehensive review of the evi-
dence for vitamin D and cancer prevention, concluding that
vitamin D may play a protective role in colorectal cancer,
but not for prostate cancer, and that the evidence is weak for
breast cancer (14). The conclusion by the International
Agency for Research on Cancer about the weakness of the
evidence for breast cancer has been a source of controversy
among vitamin D protagonists (15, 16), but subsequent
nested cohort studies have found no relation between breast
cancer risk and circulating levels of vitamin D (17, 18).
Nonetheless, vitamin D remains the cancer-preventing
vitamin du jour. Just search the phrase ‘‘vitamin D and
cancer’’ on the Internet to see what sorts of information
and products are now being marketed to the public. Vitamin
D is the new vitamin A, the new folic acid, the new vitamin
C, the new vitamin E.
An outstanding set of papers in this issue of the American
Journal of Epidemiology reports on ﬁndings about the re-
lation between circulating levels of vitamin D and subse-
quent cancer risk in a set of pooled cohort studies conducted
in the United States, Europe, and Asia. These studies found
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levels in the circulation and later incidence of 6 types of
cancers (upper gastrointestinal, ovary, endometrial, pancre-
atic, kidney, and non-Hodgkin lymphoma). Although these
cancers are characterized as ‘‘rarer,’’ this set of sites collec-
tively accounts for about a quarter of all deaths from cancer
in the United States. These studies offer compelling evi-
dence against the hypothesis that circulating levels of vita-
min D are relevant to risk of these cancers. This new
information is important because an International Agency
for Research on Cancer review had decided that evidence
was previously insufﬁcient to draw conclusions about these
6 cancer sites (14).
Whenever null ﬁndings are found, it is important to con-
sider the usual suspect reasons, and the authors of these
papers have done an outstanding job of that. The size of this
pooled analysis is large enough to discount concerns about
low statistical power; there is a good level of internal con-
sistency in the previously documented associations between
vitamin D levels and factors such as seasonality, race, gen-
der, diet, physical activity, and body mass index; there was
substantial interindividual variation in these cohorts; and
there did not seem to be confusion between confounding
factors or factors potentially in the causal pathway. The
question as to whether the time interval studied was the
correct one remains unanswered, however. If the geographic
ecologic associations between sun exposure and cancer risk
are, in fact, due to long-term cumulative effects of lifelong
vitamin D exposures, then cohort studies in adulthood will
not be fully informative. However, it is important to note
that this longer-term ecologic possibility is not consistent
with the other ecologic observation of seasonal variation in
cancer incidence that is often also attributed to vitamin D
levels in the circulation (19).
The onlyassociation observed in this set of 6 analyses was
a troubling one: that risk of pancreatic cancer was doubled
for those in the highest quintile of circulating vitamin D
levels. This observation is disconcerting both because pan-
creatic cancer is now the fourth leading cause of cancer
death in the United States and because the proponents of
the vitamin D hypothesis are now arguing that substantially
elevating circulating blood concentrations into that range
should be a nutritional policy objective for the general pop-
ulation (15, 16). As pointed outby Dr. Helzlsouer (20) in this
issue of the Journal, many ongoing randomized controlled
trials are now using quite high doses of vitamin D. As we
await clearer evidence of beneﬁts from those trials, we will
also need to be prepared to be vigilant about their individual
and collective power to assess any potential harms (21, 22).
It is timely for us to now reﬂect on the history of the past
25 years of our alphabetical approach to studying single
vitamin deﬁciency states as causal factors for cancer. We
have learned some hard lessons along the alphabetical way.
We now know that supernutritional levels of vitamins taken
as supplements do not emulate the apparent beneﬁts of diets
high in foods that contain those vitamins (13), and we now
know that taking vitamins in supernutritional doses can
cause serious harm. In short, we have found that the reality
of human biology is far more complex than is suggested by
our simple ideas.
Finally,it is important torecognize the efforts of the many
Vitamin D Pooling Project of Rarer Cancers collaborators
who carried out such a remarkable set of studies. As pointed
out by the Institute of Medicine, we are now in an era of
‘‘big science,’’ in which deﬁnitive answers to big questions
will increasingly require massive efforts and large-scale col-
laborations (23). Carrying out these types of collaborations
requires foresight, skill, and patience. Large-scale collabo-
rations are critically important, though, for our improved
understanding of the true nature of the determinants of hu-
man health. The dual problems of type 1 and type 2 errors
have best been exempliﬁed in genetic epidemiology, but
false discovery has been a problem in nutritional epidemi-
ology as well. Even though there was consistency in the
overall null observations across most of the cohorts in this
pooled analysis, therewas somevariation. It is easy to imag-
ine that, without this collaborative analysis, we might have
been led down several blind alleys derived from analyses of
various subgroups and interactions. We all should be grate-
ful to the Vitamin D Pooling Project of Rarer Cancers in-
vestigators for having saved us from years of false leads, as
well as for their vision and skill in carrying out this out-
standing collaborative project.
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